Efficacy and Safety Study to Evaluate MT-6548 in Non-dialysis Subjects With Anemia Associated With Chronic Kidney Disease in Japan

PHASE3CompletedINTERVENTIONAL
Enrollment

304

Participants

Timeline

Start Date

October 30, 2017

Primary Completion Date

January 8, 2019

Study Completion Date

August 9, 2019

Conditions
Anemia; Non-dialysis Dependent Chronic Kidney Disease
Interventions
DRUG

MT-6548

Oral tablet

DRUG

Darbepoetin alfa

Subcutaneous

Trial Locations (31)

Unknown

Research site, Aichi

Research site, Chiba

Research site, Fukui

Research site, Fukuoka

Research site, Fukushima

Research site, Gunma

Research site, Hiroshima

Research site, Hokkaido

Research site, Hyōgo

Research site, Ibaraki

Research site, Kagoshima

Research site, Kanagawa

Research site, Kochi

Research site, Kumamoto

Research site, Kyoto

Research site, Miyagi

Research site, Nagano

Research site, Nagasaki

Research site, Nara

Research site, Niigata

Research site, Okayama

Research site, Okinawa

Research site, Osaka

Research site, Ōita

Research site, Saga

Research site, Saitama

Research site, Shiga

Research site, Shizuoka

Research site, Tokyo

Research site, Toyama

Research site, Yamanashi

All Listed Sponsors
lead

Mitsubishi Tanabe Pharma Corporation

INDUSTRY